

SKIDMORE

Mosby's[®]

2024

NURSING DRUG REFERENCE

37TH EDITION

Administer drugs safely, accurately,
and professionally.



ELSEVIER

Evolve[®]

Student Resources on Evolve
Access Code Inside

Evolve®

YOU'VE JUST PURCHASED MORE THAN A TEXTBOOK!



Enhance your learning with Evolve Student Resources.

These online study tools and exercises can help deepen your understanding of textbook content so you can be more prepared for class, perform better on exams, and succeed in your course.

Activate the complete learning experience that comes with each NEW textbook purchase by registering with your scratch-off access code at

[http://evolve.elsevier.com/
nursingdrugupdates/Skidmore/NDR/](http://evolve.elsevier.com/nursingdrugupdates/Skidmore/NDR/)

If your school uses its own Learning Management System, your resources may be delivered on that platform. Consult with your instructor.

If you rented or purchased a used book and the scratch-off code at right has already been revealed, the code may have been used and cannot be re-used for registration. To purchase a new code to access these valuable study resources, simply follow the link above.

REGISTER TODAY!

Place
Sticker
Here



ELSEVIER

You can now purchase
Elsevier products on Evolve!
Go to evolve.elsevier.com/shop
to search and browse for products.

2019v1.0

Life-threatening side effects are emphasized

Common unlabeled uses and doses are clearly indicated

972 oxazepam

- Hepatic studies before each cycle (bilirubin, AST, ALT, LDH) as needed or monthly
- **Bleeding:** hematuria, guaiac, bruising or petechiae, mucosa or orifices; obtain prescription for viscous lidocaine (Xylocaine)
- All medications PO if possible; avoid IM inj when platelets <100,000/mm³
- **Pregnancy/breastfeeding: do not use in pregnancy, breastfeeding, use contraception**

Evaluate:

- Therapeutic response: decreased tumor size, spread of malignancy

Teach patient/family:

- **To report signs of infection:** increased temperature, sore throat, flu-like symptoms
- To report signs of **anemia:** fatigue, headache, faintness, SOB, irritability
- To report **bleeding:** to avoid use of razors, commercial mouthwash
- To avoid aspirin, ibuprofen, NSAIDs, alcohol, may cause GI bleeding
- **To report any changes in breathing, coughing**
- To report numbness, tingling in face or extremities, poor hearing, or joint pain or swelling
- Not to receive live virus vaccines during treatment
- **Dysesthesias:** to avoid contact with cold (air, ice, liquid)
- **To use contraception during treatment and for 4 mo after; that product may cause infertility**

USES: Anxiety, alcohol withdrawal
Unlabeled uses: Insomnia

CONTRAINDICATIONS: Pregnancy, breastfeeding, children <6 yr, hypersensitivity to benzodiazepines, closed-angle glaucoma, psychosis
Precautions: Geriatric patients, debilitated patients, renal/hepatic disease, depression, suicidal ideation, dementia, sleep apnea, seizure disorder

Black Box Warning: Depressants, respiratory depression

DOSAGE AND ROUTES

- Anxiety**
- **Adult /child ≥12 yr:** PO 10-15 mg tid-qid, max 120 mg/day
- **Geriatric:** PO 10 mg daily-bid, max 60 mg/day tid
- Alcohol withdrawal**
- **Adult:** PO 15-30 mg tid-qid
- Severe anxiety syndrome, agitation, anxiety with depression**
- **Adult/child >12 yr:** PO 15-30 mg tid
- Available forms:** Caps 10, 15, 30 mg
- Administer:**
- Without regard to food
- Taper product (0.5 mg q3days) before discontinuing

SIDE EFFECTS

- CNS:** Dizziness, drowsiness, confusion, headache, anxiety, tremors, fatigue, depression, insomnia, hallucinations, paradoxical excitement, transient amnesia
- CV:** Orthostatic hypotension, ECG changes, tachycardia, hypotension
- EENT:** Blurred vision, tinnitus, mydriasis
- GI:** Nausea, vomiting, anorexia, drug-induced hepatitis
- HEMA:** Leukopenia
- INTEG:** Rash, dermatitis, itching
- SYST:** Dependence

PHARMACOKINETICS

Peak 2-4 hr; metabolized by liver; excrete by kidneys; half-life 5-15 hr; crosses placenta, breast milk; protein binding 97%

Canada only

© Genetic warn

High Alert header highlights drugs that pose the greatest risk if administered improperly

Black Box Warnings identify serious and life-threatening adverse effects

Controlled Substance Schedules appear in an easy-to-spot header

Subheads indicate specific administration for dosing and routes of administration

Please see the following page for more features.

Nursing considerations provide guidance throughout the nursing process

INTERACTIONS

Black Box Warning: Increase: oxazepam effects, respiratory depression—CNS depressants, alcohol, disulfiram, opioids

Decrease: oxazepam effects—oral contraceptives, phenytoin, theophylline, valproic acid

Decrease: effects of levodopa

Drug/Herb

Increase: CNS depression—kava, melatonin, valerian

Drug/Lab Test

Increase: AST, ALT, serum bilirubin

Decrease: WBC

NURSING CONSIDERATIONS

Assess:

- CBC and LFTs periodically in longer-term therapy

Black Box Warning: Respiratory depression: not to be used in preexisting respiratory depression; use cautiously in severe pulmonary disease; monitor respirations, avoid use with opioids or other CNS depressants

- **Mental status:** mood, sensorium, affect, sleeping pattern, drowsiness, dizziness, sedation, suicidal thoughts/behaviors

• **Physical dependency, withdrawal symptoms:** headache, nausea, vomiting, muscle pain, weakness, tremors, seizures (long-term use)

- **Beers:** avoid in older adults; delirium, cognitive impairment may occur

• **Pregnancy/breastfeeding:** assess for pregnancy before use; do not use in pregnancy; do not breastfeed

Evaluate:

- Therapeutic response: decreased anxiety, restlessness, insomnia

Teach patient/family:

- That product may be taken without regard to food
- That medication is not to be used for everyday stress or used >4 mo unless directed by prescriber; not to take more than prescribed dose because product may be habit forming

OXcarbazepine 973

- To avoid OTC preparations (cough, cold, hay fever) unless approved by prescriber
- To avoid driving, activities that require alertness because drowsiness may occur
- To avoid alcohol, other psychotropic products unless directed by prescriber
- Not to discontinue product abruptly after long-term use
- To rise slowly because fainting may occur, especially among geriatric patients
- That drowsiness may worsen at beginning of treatment
- To notify prescriber if pregnancy is planned or suspected

OXcarbazepine (Rx)

(ox'kar-baz'uh-peen)

Trileptal, Oxtellar XR

Func. class.: Anticonvulsant, miscellaneous

Chem. class.: CarBAMazepine analog

Do not confuse:

OXcarbazepine/carBAMazepine

ACTION: May inhibit nerve impulses by limiting influx of sodium ions across cell membrane in motor cortex

USES: Partial seizures

CONTRAINDICATIONS:

Hypersensitivity

Precautions: Pregnancy, breastfeeding children <4 yr, hypersensitivity to carBAMazepine, renal disease, fluid restriction, hyponatremia, abrupt discontinuation, suicidal ideation, **+** positive for HLA-B 1502 allele

DOSAGE AND ROUTES

Partial seizures, adjunctive therapy

- **Adult:** PO IR 300 mg bid, may be increased by 600 mg/day in divided doses bid at weekly intervals; maintenance 1200 mg/day; **ext rel:** 600 mg daily × 1 wk, increase weekly in 600 mg/day increments to 1200-2400 mg daily

Side effects: *italicized* = common; **red** = life-threatening

Easily confused drug names are located beneath the header

Genetic warning icon highlights drugs with genetic contraindications

Mosby's[®]

2024

**NURSING
DRUG
REFERENCE**

3251 Riverport Lane
St. Louis, Missouri 63043

MOSBY'S® 2024 NURSING DRUG REFERENCE, ISBN: 978-0-443-11890-6
THIRTY-SEVENTH EDITION ISSN: 1044-8470

Copyright © 2024 by Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies, and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency can be found on our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Previous editions copyrighted 2023, 2022, 2021, 2020, 2019, 2018.

International Standard Book Number: 978-0-443-11890-6

Executive Content Strategist: Sonya Seigafuse
Content Development Manager: Danielle Frazier
Senior Content Development Specialist: Sarah Vora
Publishing Services Manager: Julie Eddy
Senior Project Manager: Jodi M. Willard
Design Direction: Margaret Reid

Printed in Canada

Last digit is the print number: 9 8 7 6 5 4 3 2 1



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org

Mosby's[®]
2024

NURSING DRUG REFERENCE

37TH EDITION



LINDA SKIDMORE-ROTH, RN, MSN, NP

Consultant

Littleton, Colorado

Formerly, Nursing Faculty
New Mexico State University
Las Cruces, New Mexico
El Paso Community College
El Paso, Texas



ELSEVIER

Consultants**Abimbola Farinde, PhD, PharmD**

Professor
College of Business
Columbia Southern University
Phoenix, Arizona

James Graves, PharmD

Clinical Pharmacist
University of Missouri Health Center
Columbia, Missouri

Charla K. Hollin, RN, BSN

Allied Health Division Chair
University of Arkansas Rich Mountain
Mena, Arkansas

**Kathleen S. Jordan, DNP, MS,
FNP-BC, ENP-BC, ENP-C,
SANE-P, FAEN, FAANP**

Clinical Associate Professor
School of Nursing
The University of North Carolina—
Charlotte
Charlotte, North Carolina
Nurse Practitioner
Mid-Atlantic Emergency Medical Associates
Phoenix, Arizona

Meera K. Brown, PharmD

Senior Manager
CVS Health
Austin, Texas

Travis E. Sonnett, PharmD

Inpatient Pharmacy Supervisor/RPD/CPS
Mann-Grandstaff VA Medical Center
Spokane, Washington;
Adjunct Faculty
Washington State University
College of Pharmacy
Spokane, Washington

Preface

Increasingly, patients are relying on nurses to know every detail of health care. More important, nurses are expected to have these answers, especially when it comes to medication. Let *Mosby's 2024 Nursing Drug Reference* be your answer. Our indispensable, yet compact, resource contains hundreds of monographs with several easy-to-use features.

NEW FEATURES

This edition features:

- Over 25 new drugs Included are monographs for:
pacritinib (Vonjo)- for myelofibrosis
deucravacitinib (Sotyktu)- for moderate to severe plaque psoriasis
terlipressin (Terlivaz)- for Hepatorenal Syndrome
- An ebook with easy-to-use navigation for quick access to monographs of your choice

NEW FACTS

This edition features more than 2000 new drug facts, including:

- New drugs and dosage information
- Newly researched side effects and adverse reactions
- New and revised Black Box Warnings
- The latest precautions, interactions, and contraindications
- IV therapy updates
- Revised nursing considerations
- Updated patient/family teaching guidelines
- Updated BEERS information
- Additional combination products
- Content previously included in appendixes has been moved to the monograph section for easier accessibility


ORGANIZATION

This reference is organized into two main sections:

- Individual drug monographs (in alphabetical order by generic name)
- Appendixes (identified by the wide thumb tabs on the edge)

The guiding principle behind this book is to provide fast, easy access to drug information and nursing considerations. Every detail—the paper, typeface, cover, binding, use of color, and appendixes—has been carefully chosen with the user in mind.

INDIVIDUAL DRUG MONOGRAPHS

This book contains monographs for more than 1300 generic and 4500 trade medications. Common trade names are given for all drugs regularly used in the United States and Canada, with drugs available only in Canada identified by a maple leaf .

The following information is provided, whenever possible, for safe, effective administration of each drug:

High-alert status: Identifies high-alert drugs with a label and icon. Visit the Institute for Safe Medication Practices (ISMP) at <http://www.ismp.org> for a list of medications and drug classes with the greatest potential for patient harm if they are used in error.

Tall man lettering: Uses the capitalization of distinguishing letters to avoid medication errors and is required by the FDA for drug manufacturers.

Pronunciation: Helps the nurse master complex generic names.

Rx/OTC: Identifies prescription or over-the-counter drugs.

Functional and chemical classifications: Allow the nurse to see similarities and dissimilarities among drugs in the same functional but different chemical classes.

Do not confuse: Presents drug names that might easily be confused within each appropriate monograph.

Action: Describes pharmacologic properties concisely.

Uses: List the conditions the drug is used to treat.

Unlabeled uses: Describe drug uses that may be encountered in practice but are not yet FDA approved.

Dosages and routes: List all available and approved dosages and routes for adult, pediatric, and geriatric patients.

Available forms: Include tablets, capsules, extended-release, injectables (IV, IM, SUBCUT), solutions, creams, ointments, lotions, gels, shampoos, elixirs, suspensions, suppositories, sprays, aerosols, and lozenges.

Side effects: Group these reactions by body system, with common side effects *italicized* and life-threatening reactions (those that are potentially fatal and/or permanently disabling) in **red type** for emphasis. *It is important to note that in some electronic versions of Mosby's 2024 Nursing Drug Reference, the red type may appear as black, bold print.*

Contraindications: List conditions under which the drug absolutely should not be given.

Precautions: List conditions that require special consideration when the drug is prescribed.

Black Box Warnings: Identify FDA warnings that highlight serious and life-threatening adverse effects.

Pharmacokinetics: Outline metabolism, distribution, and elimination.

Interactions: Include confirmed drug interactions, followed by the drug or nutrient causing that interaction, when applicable.

Drug/herb: Highlights potential interactions between herbal products and prescription or OTC drugs.

Drug/food: Identifies many common drug interactions with foods.

Drug/lab test: Identifies how the drug may affect lab test results.

Nursing considerations: Identify key nursing considerations for each step of the nursing process: Assess, Administer, Evaluate, and Teach Patient/Family. Instructions for giving drugs by various routes (e.g., PO, IM, IV) are included, with route subheadings in bold.

Compatibilities: List syringe, Y-site, additive compatibilities, and solution compatibilities if applicable and incompatibilities. If no compatibilities are listed for a drug, the necessary compatibility testing has not been done and that compatibility information is unknown. To ensure safety, assume that the drug may not be mixed with other drugs unless specifically stated.

Genetic icon : Highlights drugs with genetic contraindications.

Treatment of overdose: Provides drugs and treatment for overdoses where appropriate.

APPENDIXES

Selected New Drugs: Includes comprehensive information on over 30 key drugs approved by the FDA during the past 12 months.

Ophthalmic, Otic, Nasal, and Topical Products: Provides essential information for more than 80 ophthalmic, otic, nasal, and topical products commonly used today, grouped by chemical drug class.

Vaccines and Toxoids: Features an easy-to-use table with generic and trade names, uses, dosages and routes, and contraindications for over 40 key vaccines and toxoids.

Recently Approved Drugs: Highlights the most recently approved drugs for the market.

I am indebted to the nursing and pharmacology consultants who reviewed the manuscript and thank them for their criticism and encouragement. I would also like to thank Danielle Frazier and Sarah Vora, my editors, whose active encouragement and enthusiasm have made this book better than it might otherwise have been. I am likewise grateful to Cassie Carey and Jodi Willard for the coordination of the production process and assistance with the development of the new edition. A special “thank-you” to my son, Craig Roth, for completing the electronic files.

Linda Skidmore-Roth

Contents

INDIVIDUAL DRUG MONOGRAPHS, 1

APPENDIXES, 1393

A. Selected New Drugs, 1393

abrocitinib	oteseconazole
daxibotulinumtoxinA-lan	pacritinib
deucravacitinib	sodium phenylbutyrate/taurursodiol
eflapegrastim	spesolimab
elivaldogene autotemcel	sutimlimab-jome
faricimab-svoa	tapinarof
futibatinib	tebentafusp-tebn
ganaxolone	teclistamab
mavacamten	teplizumab-mzww
mirvetuximab	terlipressin
mitapivat	tirzepatide
nivolumab/relatlimab	tremelimumab
olipudase alfa	zutrisiran

B. Ophthalmic, Nasal, Topical, and Otic Products, 1409

C. Vaccines and Toxoids, 1422

D. Recent FDA Drug Approvals, 1427

INDEX, 1428

EVOLVE WEBSITE

- Additional Monographs
- Drug Categories

⚠ HIGH ALERT**abacavir (Rx)**

(ah-bak'ah-veer)

Ziagen*Func. class.:* Antiretroviral*Chem. class.:* Nucleoside reverse transcriptase inhibitor (NRTI)**Do not confuse:****abacavir/amprenavir****ACTION:** Inhibitory action against HIV-1; inhibits replication of the virus by incorporating into cellular DNA by viral reverse transcriptase, thereby terminating the cellular DNA chain**USES:** In combination with other antiretroviral agents for HIV-1 infection**Unlabeled uses:** HIV prophylaxis following occupational exposure**CONTRAINDICATIONS****Black Box Warning:** Hypersensitivity, moderate/severe hepatic disease, lactic acidosis**Precautions:** Pregnancy, breastfeeding, children <3 mo, granulocyte count <1000/mm³ or HB <9.5 g/dL, severe renal disease, impaired hepatic function, HLA B5701+ (Black, White, Asian patients), abrupt discontinuation; Guillain-Barré syndrome, immune reconstitution syndrome, MI, obesity, polymyositis**DOSAGE AND ROUTES****• Adult and adolescent ≥16 yr:** PO 300 mg bid or 600 mg/day with other antiretrovirals**• Adolescent <16 yr and child ≥3 mo:** PO (oral solution) 8 mg/kg bid or 16 mg/kg daily, max 300 mg bid with other antiretrovirals; tablets 14-19 kg 150 mg bid or 300 mg daily; 20-24 kg 150 mg AM and 300 mg PM or 450 mg daily; ≥25 kg 300 mg bid or 600 mg daily**Hepatic dose****• Adult: PO (Child-Pugh A [5-6 points]) (oral solution) 200 mg bid; moderate to severe hepatic disease, do not use****HIV prophylaxis (unlabeled)****• Adult: PO** 600 mg daily as an alternative
Available forms: Tablets 300 mg; oral solution 20 mg/mL**Administer:**

- Give in combination with other antiretrovirals
- May give without regard to food q12hr around the clock
- Reduce dose in hepatic disease, use oral sol
- Storage at room temperature; protect from light; oral solution stored at room temperature; do not freeze

SIDE EFFECTS**CNS:** *Fever, headache, malaise, insomnia, lethargy***GI:** *Nausea, vomiting, diarrhea, anorexia, increase AST/ALT, hepatotoxicity, hepatomegaly with steatosis***INTEG:** *Rash, urticaria, hypersensitivity reactions***META:** *Lactic acidosis***OTHER:** *Fatal hypersensitivity reactions, MI, fat redistribution, immune reconstitution***PHARMACOKINETICS**

Rapid/extensive absorption, distributed to extravascular space, then erythrocytes; 50% protein binding; extensively metabolized to inactive metabolites by the liver; half-life 1½ hr; excreted in urine, feces (unchanged); onset, peak, 1-1.5 hr; duration unknown

INTERACTIONS

- **Do not coadminister with abacavir-containing products, ribavirin, interferon**
- **Increase:** possible lactic acidosis—ribavirin


Increase: abacavir levels—alcohol**Decrease:** levels of methadone, may require higher dose of methadone**Drug/Lab Test****Increase:** serum glucose, triglycerides, ALT, AST, amylase, CK**NURSING CONSIDERATIONS****Assess:**

- Symptoms of HIV and possible infections; increased temperature baseline and throughout treatment

Black Box Warning: Lactic acidosis

(elevated lactate levels, increased LFTs), severe hepatomegaly with steatosis, discontinue and do not restart; may have enlarged liver, elevated AST, ALT, lactate levels; women and the obese may be at greater risk; monitor serum lactate levels, LFTs, palpate liver for enlargement

Black Box Warning: Fatal hypersensitivity reactions:

fever, rash, nausea, vomiting, fatigue, cough, dyspnea, diarrhea, abdominal discomfort; treatment should be discontinued and not restarted; those with  HLA-B5701 are at great risk for hypersensitivity; obtain testing for HLA-B 5701 prior to starting treatment, register at the Abacavir Hypersensitivity Registry (800-270-0425)

- Renal studies: BUN; serum uric acid; CCr prior to, during therapy; these may be elevated

Black Box Warning: Hepatotoxicity:

monitor hepatic studies prior to and monthly during therapy: bilirubin, AST, ALT, amylase, alkaline phosphatase, creatine phosphokinase, creatinine

- **Blood counts:** monitor viral load and CD4 counts during treatment; watch for decreasing granulocytes, HB; if low, therapy may have to be discontinued and restarted after recovery; blood transfusions may be required; perform hepatitis B virus (HBV) screening to confirm correct treatment
- **Resistance:** do not use triple antiretrovirals (abacavir, lamivudine, tenofovir) in treatment-naïve persons
- **Immune reconstitution syndrome:** may occur anytime during treatment and is a response to CMV, *Mycobacterium avium* infection
- **Fat redistribution:** may occur anytime during treatment; buffalo hump, breast growth, moon face, facial wasting, trunk obesity

Evaluate:

- Therapeutic response: increased CD4 count, decreased viral load, decreased disease progression

Teach patient/family:

- That product is not a cure but will control symptoms; that patient is still infective, may pass HIV virus on to others, not to have sexual contact without condom, needles should not be shared, blood from infected individual should not come in contact with another's mucous membranes
- To carry emergency ID with condition, products taken; not to take other products that contain abacavir
- That body fat redistribution may occur; not to share product
- **Hypersensitivity: to notify prescriber of sore throat, swollen lymph nodes, malaise, fever; other infections may occur; stop product and to notify prescriber immediately if skin rash, fever, cough, shortness of breath, GI symptoms occur; to advise all health care providers that allergic reaction has occurred with abacavir**
- That follow-up visits must be continued because serious toxicity may occur; blood counts must be done
- To review and discuss points outlined on Medication Guide and Warning Card
- That other products may be necessary to prevent other infections and that drug is taken with other antiretrovirals
- Not to drink alcohol while taking this product
- To use exactly as prescribed, not to stop product or change dose, not to use with other products unless approved by prescriber
- **Pregnancy/breastfeeding: to consider the use of contraception during treatment; identify if pregnancy is planned or suspected; use only if benefits outweigh risk; pregnant patients should enroll in Antiretroviral Pregnancy Registry at 800-258-4263; avoid breastfeeding**

abaloparatide (Rx)

(a-bal-oh-PAR-a-tide)

Tymlos*Func. class.:* Parathyroid hormone analog and modifier

ACTION: A synthetic peptide analog of a parathyroid hormone–related protein, which acts as an agonist at the PTH receptors

USES: For the treatment of postmenopausal women with osteoporosis at high risk for fracture

CONTRAINDICATIONS:

Hypersensitivity

Precautions: Breastfeeding, children, pregnancy, radiation, hypercalcemia, hypercalciuria, hyperuricemia, hyperparathyroidism, renal disease, orthostatic hypotension

Black Box Warning: Osteogenic sarcoma, new primary malignancy

DOSAGE AND ROUTES

Postmenopausal women with osteoporosis at high risk for fracture

• **Adult postmenopausal female:** SUBCUT 80 mcg daily

Available forms: Solution for injection 80 mcg/dose

Administer: SUBCUT route

- Visually inspect for particulate matter and discoloration prior to use
- Do not use IV/IM
- Needles are not included with the pen; a separate prescription for needles is needed. Use 8-mm, 31-gauge Clickfine needles such as ReliOn, Smart Sense, or TopCare brands
- Prime prior to first use to remove air bubbles
- Do not inject into areas where skin is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch marks

- Rotate site daily and give at the same time
- The first several doses should be given with the patient lying down in case of orthostatic hypotension

• **Storage:** Prior to first use, store pen in refrigerator (do not freeze). After first use, store for up to 30 days at room temperature (68°F–77°F or 20°C–25°C); do not freeze or expose to heat. Keep cap on when not in use. Do not store with a needle attached. Use pen only for 30 days. Dispose of properly

SIDE EFFECTS**CNS:** Dizziness**META:** Hypercalcemia, hyperuricemia**INTEG:** Injection site reactions**CV:** Orthostatic hypotension**PHARMACOKINETICS**

Protein binding approximately 70%; half-life 0.7 hr

INTERACTIONS

None known

NURSING CONSIDERATIONS**Assess:**

- **Osteoporosis:** prior to and during treatment
- **Blood studies:** serum calcium, uric acid baseline and periodically
- **Urolithiasis:** product may increase the risk of urolithiasis in those with recent or current urolithiasis

Black Box Warning: Osteosarcoma: increased risk; use product for <2 yr

• **Pregnancy/breastfeeding:** not indicated for women of reproductive potential

Evaluate:

• Therapeutic response: increased bone mineral density

Teach patient/family:

- Not to try to inject until patient or caregiver receives training
- To receive the first several injections near a place to sit or lie down, until the effect of the injection is known; blood pressure may drop

4 abatacept

- To inject 1 time each day into lower stomach area (abdomen) just under the skin (SUBCUT); to avoid giving the injection within the 2-inch area around the navel; to rotate injection sites daily
- That periodic lab tests will be done
- To take at same time each day; that if the dose is forgotten or cannot be taken at the usual time, to take drug as soon as remembered on that day
- Not to share pen or pen needles with others even if the needle has been changed
- **Urolithiasis:** to report painful urination

abametapir (Rx)

(a'ba-met'a-pir)

Keglyze

Func. class.: Pediculicide

Chem. class.: Metalloproteinase inhibitor

ACTION:

Inhibits metalloproteinases that are critical to egg development and survival of lice

USES:

Head lice

CONTRAINDICATIONS

Hypersensitivity

Precautions: Risk of neonatal benzyl alcohol toxicity, accidental ingestion

DOSAGE AND ROUTES

• **Adult/child ≥ 6 mo:** **Topical** apply to whole scalp and hair using up to the whole bottle

Available forms: Lotion 0.74%

Administer:

Topical

- For topical use only
- Shake well before using, apply to dry hair to cover whole area to be treated, including hair and scalp
- Massage into the scalp and hair, leave on for 10 min, then rinse with warm water
- For single use only, discard unused portion
- Do not flush unused portion down sink or toilet
- Wash hands after use
- Store at room temperature

SIDE EFFECTS

GI: Vomiting

EENT: Eye irritation, burning

INTEG: Dermatitis, rash, head/scalp pruritus, hair color change

PHARMACOKINETICS:

Onset rapid, peak 34-92 min, duration unknown, half-life 12 hr

INTERACTIONS:

Increase: CYP1A2/CYP2B6/CYP3A4 substrates: avoid use 2 wk before application

NURSING CONSIDERATIONS

Assess:

• **Infestation:** Assess head, hair for lice, nits before and after treatment; identify source of infection: school, family

• **Pregnancy/breastfeeding:** Use only if needed, no studies in pregnancy or lactation

Evaluate:

• **Therapeutic response:** Absence of nits, brownish trails on scalp

Teach patient/family:

• To wash all inhabitants' clothing, brushes, bedding; that preventive treatment may be required of all persons living in same house, using lotion to decrease spread of infection

• Do not ingest

• Keep out of reach of children

• Use on children under the direct supervision of an adult, risk of benzyl alcohol toxicity

• Avoid contact with eyes

• Wash hands after application

• Shampoo hair any time after the treatment

• Use only once, do not reapply

• Discard unused portion, do not flush contents down sink/toilet

abatacept (Rx)

(ab-a-ta'sept)

Orencia, Orencia ClickJet

Func. class.: Antirheumatic agent (disease modifying)

Chem. class.: Immunomodulator

Do not confuse:

Orencia/Oracea

ACTION: A selective costimulation modulator; inhibits T lymphocytes, inhibits production of tumor necrosis factor (TNF- α), interferon- γ , interleukin-2, which are involved in immune and inflammatory reactions

USES: Polyarticular juvenile rheumatoid arthritis; moderate to severe rheumatoid arthritis; acute, chronic rheumatoid arthritis that has not responded to other disease-modifying agents; may use in combination with DMARDs; do not use with TNF antagonists (adalimumab, etanercept, infliximab), anakinra

CONTRAINDICATIONS: Hypersensitivity

Precautions: Pregnancy, breastfeeding, children, geriatric patients, recurrent infections, COPD, TB, viral hepatitis, immunosuppression, neoplastic disease, respiratory infection

DOSAGE AND ROUTES**Rheumatoid arthritis/psoriatic arthritis**

- **Adult:** SUBCUT 125 mg within 1 day after single IV loading dose, then 125 mg weekly; weekly SUBCUT dose may be initiated without an IV loading dose for those unable to receive an infusion

- **Adult >100 kg (220 lb):** IV INFUSION 1 g over 30 min, give at 2, 4 wk after first infusion, then q4wk

- **Adult 60-100 kg (132-220 lb):** IV INFUSION 750 mg over 30 min, give at 2, 4 wk after first infusion, then q4wk

- **Adult <60 kg (132 lb):** IV INFUSION 500 mg over 30 min, give at 2, 4 wk after first infusion, then q4wk

Juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA)

- **Adolescent and child ≥ 6 yr and >100 kg:** IV INFUSION 1 g given over 30 min q2wk \times 3 doses, then 1 g given over 30 min q4wk starting at wk 8

- **Adolescent and child ≥ 6 yr and 75-100 kg:** IV INFUSION 750 mg over 30

min q2wk \times 2 doses, then 750 mg given over 30 min q4wk starting at wk 8

- **Adolescent and child ≥ 6 yr and <75 kg:** IV INFUSION 10 mg/kg given over 30 min q2wk \times 3 doses, then 10 mg/kg q4wk starting at wk 8

Moderate/severe polyarticular juvenile idiopathic arthritis as monotherapy with or without methotrexate

- **Child/adolescent ≥ 2 yr and ≥ 50 kg:** SUBCUT 125 mg q1wk

- **Child/adolescent ≥ 2 yr and 25-50 kg:** SUBCUT 87.5 mg q1wk

- **Child/adolescent ≥ 2 yr and 10-25 kg:** SUBCUT 50 mg q1wk

Available forms: Lyophilized powder, single-use vials 250 mg; sol for SUBCUT injection 125 mg/mL

Administer:

- Storage in refrigerator; do not use expired vials, protect from light, do not freeze

Intermittent IV INFUSION route

- **To reconstitute,** use 10 mL sterile water for injection; insert syringe needle into vial and direct stream of sterile water for injection on the wall of vial; rotate vial until mixed; vent with needle (25 mg/mL); **further dilute** in 100 mL NS from a 100-mL infusion bag/bottle; withdraw the needed volume (2 vials remove 20 mL, 3 vials remove 30 mL, 4 vials remove 40 mL); slowly add the reconstituted solution from each vial into the infusion bag/bottle using the same disposable syringe supplied; mix gently; discard unused portions of vials; do not use if particulate is present or discolored; **give** over 30 min; use non-protein-binding filter (0.2-1.2 microns); protect from light

- Do not admix with other solutions or medications

SUBCUT route

- Use prefilled syringe for SUBCUT only (do not use for IV); allow to warm to room temperature (30-60 min); inject into fronts of thighs, outer area of upper arm, or abdomen except for 2-inch area

around the navel; do not inject into tender, bruised area

- Rotate injection sites
- Use ClickJet for SUBCUT only; let warm for 30 min after removal from refrigerator; do not use if damaged or past expiration date

SIDE EFFECTS

CNS: Headache, asthenia, dizziness

CV: *Hypo/hypertension*

GI: Abdominal pain, dyspepsia, nausea, diarrhea, diverticulitis

GU: UTI, pyelonephritis

MS: Back pain

INTEG: Rash, *injection site reaction*, flushing, urticaria, pruritus

RESP: *Pharyngitis, cough, URI, non-URI, rhinitis, wheezing*

SYST: *Anaphylaxis, malignancies, serious infections, antibody development*

PHARMACOKINETICS

Half-life IV 13 days, SUBCUT 14.3 days, steady state 60 days; clearance increases with increased body weight

INTERACTIONS

- Do not give concurrently with live virus vaccines; immunizations should be brought up to date prior to treatment
- Do not use with TNF antagonists: adalimumab, etanercept, infliximab; anakinra; infection may occur
- Avoid use with corticosteroids, immunosuppressives, atropine, scopolamine, halothane, nitrous oxide

NURSING CONSIDERATIONS

Assess:

- **RA:** pain, stiffness, ROM, swelling of joints during treatment baseline and periodically
- **HBV reactivation:** Screen patient at risk prior to starting treatment
- **TB:** for latent/active TB, viral hepatitis prior to beginning treatment
- For injection site pain, swelling
- Patient's overall health at each visit; product should not be given with active infections; parenteral product contains maltose, glucose monitoring must be done with glucose-specific testing

• **Infection:** sinusitis, UTI, influenza, bronchitis; serious infections have occurred; notify prescriber, therapy may need to be changed

• **Pregnancy/breastfeeding:** assess whether pregnancy is planned or suspected; if pregnant, register by calling 877-311-8972; use only if benefits outweigh fetal risk; do not breastfeed

Evaluate:

• Therapeutic response: decreased inflammation, pain in joints

Teach patient/family:

- That product must be continued for prescribed time to be effective, not to use with alcohol
- To use caution when driving; dizziness may occur
- Not to have live virus vaccinations while taking this product or use alcohol, TNF antagonists, other immunosuppressants; bring vaccinations up to date prior to use of this product
- About patient information included in packaging, including “do not shake”
- How to inject and rotate injection sites
- To immediately report signs of infection: temperature, flu like symptoms, urinary burning/stinging, sinusitis
- To avoid those with known infections
- That product contains maltose and may lead to elevated glucose levels in some glucose testing methods
- To inform all prescribers that this product is being used

abemaciclib (Rx)

(uh-beh'-muh-sy'-klib)

Verzenio

Func. class.: Antineoplastic

Chem. class.: Kinase inhibitors

ACTION: It is an inhibitor of the cyclin-dependent kinases 4 and 6, a protein kinase inhibitor

USES: For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression

following endocrine therapy and prior chemotherapy, as monotherapy, or in combination with fulvestrant

CONTRAINDICATIONS: Hypersensitivity

Precautions: Breastfeeding, contraception requirements, hepatic disease, hepatotoxicity, infertility, neutropenia, pregnancy, pregnancy testing, reproductive risk, thromboembolic disease

DOSAGE AND ROUTES

HR-positive, HER2-negative advanced or metastatic breast cancer disease progression following endocrine therapy and prior chemotherapy, as monotherapy

• **Adult:** PO 200 mg bid until disease progression or unacceptable toxicity

HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy, in combination with fulvestrant

• **Adult:** PO 150 mg bid with fulvestrant (500 mg IM as two 250-mg [5 mL] injections, 1 injection in each buttock, on days 1, 15, 29, and monthly thereafter) until disease progression or unacceptable toxicity. Pre- and perimenopausal women should also be treated with a gonadotropin-releasing hormone agonist

Therapeutic drug monitoring: dosage adjustments for treatment-related toxicities

Interrupt therapy per specific instructions. Restart as appropriate at the following reduced doses:

• **Starting dose:** Monotherapy, 200 mg bid; combination with fulvestrant, 150 mg bid

• **First occurrence:** Monotherapy, 150 mg bid; combination with fulvestrant, 100 mg bid

• **Second occurrence:** Monotherapy, 100 mg bid; combination with fulvestrant, 50 mg bid

• **Third occurrence:** Monotherapy, 50 mg bid; combination with fulvestrant, not applicable

Diarrhea

• **Grade 1:** Begin antidiarrheals, increase oral fluid intake. No change needed

• **Grade 2, first occurrence:** Begin antidiarrheals, increase oral fluid intake. If diarrhea does not resolve to grade ≤ 1 within 24 hr, hold until resolution. No change needed unless grade 2 diarrhea persists; upon resolution to grade ≤ 1 , resume at next lower dose level

• **Grade 2, recurrent despite maximal supportive measures:** Begin antidiarrheals, increase oral fluid intake. When diarrhea resolves to grade ≤ 1 , resume at next lower dose level

• **Grade 3 or 4, or requires hospitalization:** Begin antidiarrheals, increase oral fluid intake. When diarrhea resolves to grade ≤ 1 , resume at next lower dose level

Hepatic dose

• **Adult:** PO

Child-Pugh A or B: no change; **Child-Pugh C:** reduce dosing to once per day; **grade 1 (AST/ALT 1.1-3 \times the upper limit of normal [ULN]),** without an increase in total bilirubin above 2 \times ULN: no change; **grade 2, first occurrence (AST/ALT 3.1-5 \times ULN),** without an increase in total bilirubin above 2 \times ULN: no change; if grade 2 persists, hold; after resolution to baseline or grade 1, resume at the next lower dose level; **grade 2, recurrent (AST/ALT 3.1-5 \times ULN),** without an increase in total bilirubin above 2 \times ULN: hold; after resolution to baseline or grade 1, resume at the next lower dose level; **grade 2 or 3 (AST/ALT 3.1-20 \times ULN) with total bilirubin greater than 2 \times ULN, in the absence of cholestasis:** discontinue; **grade 4 (AST/ALT >20 \times ULN):** discontinue

Available forms

Tablets 50, 100, 150, 200 mg

Administer

- With food at the same time every day
- Swallow tablets whole; do not chew, crush, or split. Do not take if broken, cracked
- If a dose is missed, do not replace missed dose; resume with the next scheduled daily dose

SIDE EFFECTS

GI: Diarrhea, abdominal pain, anorexia, nausea, vomiting, constipation, stomatitis, weight loss

CNS: Dizziness, drowsiness, fatigue, fever

MS: Arthralgia

8 abiraterone

INTEG: Rash, alopecia

GU: Renal failure (rare)

HEMA: Anemia, leukemia, neutropenia, thrombocytopenia

MISC: Infection

PHARMACOKINETICS

Protein binding 96.3%; half-life 18.3 hr; fecal excretion 97.1%; metabolized in liver by CYP3A4

INTERACTIONS

- **Increase:** abemaciclib effect—strong or moderate CYP3A4 inhibitors; avoid concomitant use
- **Decrease:** abemaciclib effect—strong or moderate CYP3A4 inducers; avoid concomitant use

NURSING CONSIDERATIONS

Assess:

- **Diarrhea:** at the first sign of loose stools, start antidiarrheal therapy, increase oral fluids
- **Neutropenia:** CBC baseline then q2wk for the first 2 mo, then monthly for the next 2 mo, and as needed
- **Venous thromboembolism:** monitor for signs, symptoms of thrombosis, pulmonary embolism; treat as needed
- **PE:** chest pain worse when breathing deeply or coughing, coughing up blood, dizziness, fainting, tachypnea, rapid heartbeat, irregular heartbeat, shortness of breath
- **Infection:** assess for UTI, lung infection, pharyngitis, conjunctivitis, sinusitis, vaginal infection, sepsis
- **Hepatotoxicity:** monitor LFTs baseline, then q2wk × 2 mo, monthly × next 2 mo, and then as needed; interruption in therapy or delay in treatment may be needed
- **Pregnancy/breastfeeding:** Avoid in females of reproductive potential during treatment and for at least 3 wk after last dose; can cause fetal harm or death; discontinue breastfeeding during treatment and for 3 wk after final dose. Presence in breast milk unknown. Obtain pregnancy test prior to treatment

Evaluate:

- Therapeutic outcome: decrease in size of cancerous tumor

Teach patient/family:

- **Infection:** to report the following to health care provider: increased temperature, fever, shaking, chills, cough, sore throat
- **Diarrhea:** to start antidiarrheal therapy at the first sign of loose stools, increase fluids, and notify health care provider
- **Thromboembolism:** to report immediately chest pain, worse when breathing deeply or coughing, coughing up blood, dizziness, fainting, tachypnea, rapid heartbeat, irregular heartbeat, shortness of breath, pain, swelling of the extremity with redness and warmth, discoloration including a bluish color
- **Pregnancy/breastfeeding:** not to use in pregnancy, breastfeeding; to use contraception during treatment and for at least 3 wk after last dose

HIGH ALERT

abiraterone (Rx)

(a'bir-a'ter-one)

Zytiga

Func. class.: Antineoplastic

Chem. class.: Androgen biosynthesis inhibitor

ACTION: Converted to abiraterone, which inhibits CYP17, the enzyme required for androgen biosynthesis; androgen-sensitive prostate cancer responds to treatment that decreases androgens

USES: Metastatic, castration-resistant prostate cancer in combination with predniSONE

CONTRAINDICATIONS: Pregnancy, women, children, breastfeeding

Precautions: Adrenal insufficiency, cardiac disease, MI, heart failure, hepatic disease, hypertension, hypokalemia, infection, surgery, ventricular dysrhythmia, stress, trauma

DOSAGE AND ROUTES

- **Adult males:** PO 1000 mg/day with predniSONE 5 mg bid and with GnRH (gonadotropin-releasing hormone analog) or bilateral orchiectomy; with strong CYP3A4 inducers 1000 mg bid

Hepatic dose

• **Adult males (Child-Pugh B, 7-9): PO** 250 mg/day with predniSONE; permanently discontinue if AST/ALT $>5 \times$ the upper limit of normal (ULN) or total bilirubin $>3 \times$ ULN; Child-Pugh C >10 , do not use

Available forms: Tablets 250 mg

Administer:**PO route**

• Give whole on empty stomach 2 hr prior to or 1 hr after meals with full glass of water; do not crush, break, chew

• **Pregnancy:** women who are pregnant or who may become pregnant should not touch tablets without gloves

• Store tablets at room temperature

SIDE EFFECTS

CV: Angina, dysrhythmia exacerbation, atrial flutter/fibrillation/tachycardia, AV block, chest pain, edema, heart failure, MI, hypertension, QT prolongation, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia

ENDO: Hot flashes, adrenocortical insufficiency

GI: Diarrhea, dyspepsia, hepatotoxicity

GU: Increased urinary frequency, nocturia, UTI

META: Adrenocortical insufficiency, hyperbilirubinemia, hypertriglyceridemia, hypokalemia, hypophosphatemia

MS: Arthralgia, myalgia, fracture

RESP: Cough, upper respiratory infection

SYST: Infection

PHARMACOKINETICS

Onset rapid, peak 2 hr, duration unknown; 99% protein binding, converted to abiraterone (active metabolite), half-life 7%-17% hr; excreted 88% (feces), 5% (urine); high-fat food increases effect, give on empty stomach; increased effect in hepatic disease

INTERACTIONS

• **Decrease:** abiraterone effect—CYP3A4 inducers (carbamazepine, phenytoin, rifampin, rifabutin, rifapentine, PHENobarbital); dose may need to be increased

• **Increase:** action of CYP2D6/CYP2C8 substrates—dextromethorphan, thioridazine, pioglitazone; doses of these

products should be reduced; avoid concurrent use if possible

Drug/Food

Increase: abiraterone action—must be taken on an empty stomach

Drug/Lab

Increase: ALT, AST, bilirubin, triglycerides, cholesterol, alkaline phosphatase

Decrease: potassium, phosphate, testosterone, lymphocytes

NURSING CONSIDERATIONS**Assess:**

• **Prostate cancer:** monitor prostate-specific antigen (PSA), serum potassium, serum bilirubin baseline and periodically

• **Hepatotoxicity:** monitor liver function tests (AST/ALT) at baseline, every 2 wk for 3 mo, monthly thereafter in no known hepatic disease; interrupt treatment in patients without known hepatic disease at baseline who develop ALT/AST $>5 \times$ ULN or total bilirubin $>3 \times$ ULN; patients with moderate hepatic disease at baseline, measure ALT, AST, bilirubin prior to the start of treatment, every week for 1 mo, every 2 wk for the following 2 mo, monthly thereafter; if elevations in ALT and/or AST $>5 \times$ ULN or total bilirubin $>3 \times$ ULN occur in patients with moderate hepatic impairment at baseline, discontinue and do NOT restart; obtain serum total bilirubin, AST/ALT if hepatotoxicity is suspected; elevations of AST, ALT, bilirubin from baseline provide more frequent monitoring

• Monitor B/P, pulse, edema, if hypertensive, control symptoms

• **Musculoskeletal pain, joint swelling, discomfort:** arthritis, arthralgia, joint swelling, and joint stiffness, some severe; muscle discomfort that includes muscle spasms, musculoskeletal pain, myalgia, musculoskeletal discomfort, and musculoskeletal stiffness may be relieved with analgesics

• Signs, symptoms of adrenocorticoid insufficiency (anorexia, nausea, vomiting, fatigue, weight loss); corticosteroids may need to be prescribed during stress, trauma, surgery; assess monthly for hypertension, hypokalemia, fluid retention

• **QT prolongation:** monitor ECG for QT prolongation, ejection fraction in patients

10 acalabrutinib

with cardiac disease; small increases in the QTc interval such as <10 ms have occurred; monitor for arrhythmia exacerbation

Evaluate:

• Therapeutic response: Decreasing spread, progression of prostate cancer

Teach patient/family:

• **Pregnancy:** that women must not come into contact with tablets; to wear gloves if product needs to be handled; that males should wear condoms and use another form of contraception if partner is pregnant during use of product and for 1 wk after discontinuing treatment

• To report chest pain, swelling of joints, burning/pain when urinating

• Not to use with other medications, herbs without prescriber approval

• To take 2 hr prior to or 1 hr after meals; to swallow tablet whole, take with water

• That this product, predniSONE, and a GnRH need to be used together

• Not to stop abruptly without prescriber consent

• That B/P, potassium, and possible fluid retention will be monitored at least monthly

• To immediately report jaundice of skin, eyes, clay-colored stools, dark urine; that lab work will be needed during at least first 3 mo

• To discuss all other products taken with all prescribers

• If dose is missed, skip and take next regularly scheduled dose

HIGH ALERT

acalabrutinib (Rx)

(a-Kal'a-broo-tin-ib)

Calquence

Func. class.: Antineoplastic

Chem. class.: Kinase inhibitor

ACTION: Second-generation kinase inhibitor, decreases proliferation of cancer cells

USES: For the treatment of mantle cell lymphoma (MCL) in patients who have received at least 1 prior therapy

CONTRAINDICATIONS:

Hypersensitivity

Precautions: Serious infections, secondary malignancies, children, pregnancy, breastfeeding

Toxicity-related dosage changes

Refer to manufacturer's information

Available forms. Capsules 100 mg

Administer:

PO route

• Give whole; do not crush, chew, or break tablets

• Give without regard to food

• If dose is missed by >3 hr, skip and continue with regular schedule, do not take a double dose

• Store at room temperature

DOSAGE AND ROUTES

• **Adult: PO** 100 mg bid (approximately 12 hr apart) until disease progression

• **Hepatic dose:** Avoid use

SIDE EFFECTS

CNS: Headache, fatigue

EENT: Epistaxis

CV: Atrial fibrillation/flutter

GI: Anorexia, constipation, diarrhea, nausea, vomiting

HEMA: Thrombocytopenia, neutropenia, anemia

MS: Myalgia

RESP: Dyspnea, cough

INTEG: Rash

MISC: Infections, secondary malignancies

PHARMACOKINETICS

Onset rapid, peak 45 min, duration unknown, half-life 0.9 hr, active metabolite 6 hr, 97.5% protein binding

INTERACTIONS

Increase: Risk of bleeding: anticoagulants, antiplatelet, monitor for bleeding

Increase: Acalabrutinib level: CYP3A4 inhibitors (diltiazem, erythromycin, verapamil), avoid using together

Decrease: Acalabrutinib level: H2-receptor antagonists (ranitidine), separate by 2 hr

Decrease: Acalabrutinib level: PPIs, avoid concurrent use

Decrease: Acalabrutinib level: Calcium antacids, separate by 2 hr

Decrease: Acalabrutinib level: CYP3A4 inducers, reduce dose, or avoid use

NURSING CONSIDERATIONS

Assess:

- For secondary malignancies (skin cancers)
- For atrial fibrillation/flutter
- For myelosuppression, obtain CBC monthly or more often
- For severe bleeding/hemorrhage, interruption for major surgeries may be needed
- For serious infection, fever, chills, flu-like symptoms, antibiotics may be needed

Teach patient/family:

- If dose is missed, give when remembered if less than 3 hr, if more than 3 hr, skip and take the next dose at the regularly scheduled time, do not double, to swallow whole with a whole glass of water
- To notify prescriber of severe bleeding (blood in stool or urine; prolonged or uncontrolled), that product may be interrupted for surgery (fever, chills, flu-like symptoms), antibiotics may be needed
- That lab tests and follow-up exams will be needed
- Teach patient to notify prescriber of secondary malignancy (skin cancer), to use sunscreen, protective clothing. Avoid prolonged exposure to sunlight
- To report palpitations, lightheadedness, dizziness, fainting, shortness of breath, or chest discomfort
- Take at least 2 hours prior to taking cimetidine (Tagamet), famotidine (Pepcid, in Duexis), nizatidine (Axid), or ranitidine (Zantac)
- To report if pregnancy is planned or suspected, not to breastfeed during or for 2 wk following last dose
- To notify other clinicians of prescription OTC drugs and dietary or herbal supplements

acamprosate (Rx)

(a-kam-pro'sate)

Func. class.: Alcohol deterrent

Chem. class.: Synthetic amino acid neurotransmitter analog

ACTION: Not completely understood; in vitro data suggest it has affinity for type A and type B GABA receptors, lowers neuronal excitability, centrally mediated

USES: Alcohol abstinence management

CONTRAINDICATIONS: Hypersensitivity to this product or sulfites, CCr ≤ 30 mL/min

Precautions: Pregnancy, breastfeeding, infants, children, ethanol intoxication, renal impairment, depression, suicidal ideation, driving or operating machinery, geriatric patients

DOSAGE AND ROUTES

- **Adult:** PO 666 mg tid

Renal dosage

- **Adult:** PO CCr 30-50 mL/min 333 mg tid; CCr < 30 mL/min do not use

Available forms: Delayed-release tablets 333 mg

Administer:

- Without regard to food; do not crush, chew, break delayed-release tablets
- Use only after alcohol is stopped
- Store at room temperature

SIDE EFFECTS

CNS: Anxiety, depression, dizziness, headache, insomnia, paresthesias, **suicidal ideation**, tremors, abnormal dreams, chills, drowsiness

CV: Palpitations, hypertension, peripheral edema

EENT: Rhinitis, pharyngitis, abnormal vision

GI: Anorexia, constipation, diarrhea, dry mouth, abdominal pain, flatulence, nausea, vomiting, taste change, weight gain

GU: Impotence

INTEG: Rash, pruritus, increased sweating

MISC: Infection, flu-like symptoms

MS: Back pain, myalgias, arthralgia

RESP: Dyspnea, bronchitis

PHARMACOKINETICS

Onset unknown, peak 3-8 hr, duration unknown, half-life 20-33 hr

INTERACTIONS

Drug/Lab

Increase: LFTs, blood glucose, bilirubin, uric acid

12 acetaminophen

Decrease: HB/Hct, platelets

NURSING CONSIDERATIONS

Assess:

- **Mental status:** depression, abnormal dreams, suicidal thoughts/behaviors, length of alcohol use, date of discontinuing alcohol use

- B/P baseline and periodically
- **Pregnancy/breastfeeding:** use only if benefits outweigh fetal risk; cautious use in breastfeeding, excretion unknown

Evaluate:

- Therapeutic response: continued alcohol abstinence

Teach patient/family:

- To notify prescriber of depression, abnormal thoughts, **suicidal thoughts/behaviors**
- To take without regard to food; not to break, crush, chew delayed-release tablets
- Not to engage in hazardous activities until effect is known; may impair thinking; monitor skills
- Not to use alcohol, to continue treatment for alcohol addiction
- **Pregnancy/breastfeeding:** to notify prescriber if pregnancy is planned or suspected; to use effective contraception; breastfeeding effects are unknown

HIGH ALERT

acarbose (Rx)

(ay-car'bose)

Glucobay , Prandase ,
Precose

Func. class.: Oral antidiabetic

USES: Type 2 diabetes mellitus, alone or in combination with a sulfonylurea, metformin, insulin

CONTRAINDICATIONS: Breastfeeding, hypersensitivity, diabetic ketoacidosis, cirrhosis, inflammatory bowel disease, ileus, colonic ulceration, partial intestinal obstruction, chronic intestinal

disease, serum creatinine >2 mg/dL, CCR <25 mL/min

DOSAGE AND ROUTES

- **Adult:** PO 25 mg tid initially, with 1st bite of meal; maintenance dose may be increased to 50-100 mg tid; dosage adjustment at 4- to 8-wk intervals, individualized

acetaminophen (Rx, OTC) (Paracetamol)

(a-seat-a-mee'noe-fen)

222AF , Abenol , Acephen, Acephen Infant Feverall, ACET , Acetab , Apacet, APAP, Apra, Atasol , Children's FeverAll, Fortolin , Genapap, Infantaire, Mapap, NeoPAP, Novo-Gesic , PEDIAPHEN , PEDIATRIX , Q-Pap, Q-Pap Children's, Rapid Action Relief , Redutemp, Ridenol, Robigesic , Rounox , Silapap, Taminol , Tempra , T-Painol, Tylenol,  XS pain reliever

acetaminophen (IV) (Rx) Ofirmive

Func. class.: Nonopioid analgesic, antipyretic

Chem. class.: Nonsalicylate, paraaminophenol derivative

Do not confuse:

Acephen/Anacin/Aspirin 3/Anacin-3

ACTION: May block pain impulses peripherally that occur in response to inhibition of prostaglandin synthesis; does not possess antiinflammatory properties; antipyretic action results from inhibition of prostaglandins in the CNS (hypothalamic heat-regulating center)

USES: Mild to moderate pain or fever, arthralgia, dental pain, dysmenorrhea, headache, myalgia, osteoarthritis

Unlabeled uses: Migraine

CONTRAINDICATIONS: Hypersensitivity to this product, phenacetin aspartame, saccharin, tartrazine

Precautions: Pregnancy, breastfeeding, geriatric patients, anemia, renal/hepatic disease, chronic alcoholism

Black Box Warning: Hepatotoxicity

DOSAGE AND ROUTES

- **Adult/child >12 yr: PO/RECT** 325-650 mg q4-6hr prn, max 4 g/day; **weight ≥50 kg IV** 1000 mg q6hr or 650 mg q4hr prn, max single dose 1000 mg, min dosing interval 4 hr; **weight <50 kg IV** 15 mg/kg/dose q6hr or 12.5 mg/kg/dose q4hr, max single dose 15 mg/kg, min dosing interval 4 hr, max 75 mg/kg/day from all sources; **EXTENDED RELEASE** 650-1300 mg q8hr as needed, max 4 g/day
- **Child ≥2 yr and <50 kg: IV** 15 mg/kg/dose q6hr or 12.5 mg/kg/dose q4hr, max single dose 15 mg/kg, min dosing interval 4 hr, max 75 mg/kg/day from all sources

Renal dose

- **Adult: IV CCr <30 mL/min reduce dose and prolong interval, CCr <10 mL/min PO/RECT/IV minimum interval of q8hr**

Hepatic dose

- **Adult:** Mild to moderate: max 2000 mg/day; severe liver damage: contraindicated

Migraine (unlabeled)

- **Adult and adolescent: PO/RECT** 500-1000 mg, max 1 g/dose or max 4 g/day
- Available forms:** Rectal suppository 120, 325, 650 mg; soft chew tablets 80, 160 mg; capsules 500 mg; elixir 120, 160, 325 mg/5 mL; oral disintegrating tablets 80, 160 mg; oral drops 80 mg/0.8 mL, liquid 500 mg/5 mL, 160/5 mL, 1000/30 mL; extended release 650 mg, 80 mg/mL; tablets 325, 500, 650 mg; solution for injection 1000 mg/100 mL

Administer:

PO route

- **Do not confuse 2 × 325 (650 mg) with 650-mg extended-release tablets**
- Crushed or whole, do not crush extended-release product; chewable

tablets may be chewed; give with full glass of water

- With food or milk to decrease gastric symptoms if needed
- Suspension after shaken well; check elixir, liquid, suspension concentration carefully; suspension and capsules are bioequivalent

Rectal route

- Store suppositories <80°F (27°C)

Intermittent IV INFUSION route

- No further dilution needed; do not add other medications to vial or infusion device
- For doses equal to single vial, a vented IV set may be used to deliver directly from vial; for doses less than a single vial, withdraw dose and place in an empty sterile syringe, plastic IV container, or glass bottle; infuse over 15 min
- Discard unused portion; if seal is broken, vial penetrated, or drug transferred to another container, give within 6 hr

Y-site compatibilities: Do not admix

SIDE EFFECTS

CNS: Agitation (child) (IV); headache, fatigue, anxiety (IV)

RESP: Dyspnea (IV), atelectasis (child) (IV)

CV: Hyper- and hypotension (IV)

GI: Nausea, vomiting, abdominal pain; **hepatotoxicity, hepatic seizure (overdose), GI bleeding**

GU: Renal failure (high, prolonged doses)

HEMA: Leukopenia, neutropenia, hemolytic anemia (long-term use), thrombocytopenia, pancytopenia

INTEG: Rash, urticaria, injection site pain

SYST: Stevens-Johnson syndrome, toxic epidermal necrolysis

TOXICITY: Cyanosis, anemia, neutropenia, jaundice, pancytopenia, CNS stimulation, delirium followed by vascular collapse, seizures, coma, death

PHARMACOKINETICS

85%-90% metabolized by liver, excreted by kidneys; metabolites may be toxic if overdose occurs; widely distributed; crosses placenta in low concentrations; excreted in breast milk; half-life 1-4 hr

14 acetaminophen

PO: Onset 10-30 min, peak ½-2 hr, duration 4-6 hr, well absorbed

IV: Onset rapid, peak 30-120 min, duration 3-4 hr

RECT: Onset slow, peak 1-2 hr, duration 4-6 hr, absorption varies

INTERACTIONS

Increase: renal adverse reactions—NSAIDs, salicylates; consider lower dose

Increase: methemoglobinemia—nitric oxide, prilocaine; avoid concurrent use

Increase: hypoprothrombinemia—warfarin, long-term use, high doses of acetaminophen

Increase: hepatotoxicity—barbiturates, alcohol, carbamazepine, hydantoins, rifampin, rifabutin, isoniazid, diflunisal, zidovudine, lamotrigine, imatinib, dasatinib, mipomersen; monitor for hepatotoxicity

Decrease: absorption—colestipol, cholestyramine

Decrease: zidovudine, lamotrigine effect

Drug/Herb

Increase: hepatotoxicity—St. John's wort, due to acetaminophen metabolism

Drug/Lab Test

Increase: LFTs, potassium, bilirubin, LDH, prothrombin time

Decrease: HB/Hct, WBC, RBC, platelets; albumin, magnesium, phosphate (pediatrics)

NURSING CONSIDERATIONS

Assess:

- **For fever and pain:** Type of pain, location, intensity, duration, aggravating/alleviating factors; assess for diaphoresis, fever baseline and periodically

- **Hepatic studies:** AST, ALT, bilirubin, creatinine before therapy if long-term therapy is anticipated; may cause hepatic toxicity at doses >4 g/day with chronic use

- **Renal studies:** BUN, urine creatinine, occult blood, albumin, if patient is on long-term therapy; presence of blood or albumin indicates nephritis, I&O ratio; decreasing output may indicate renal failure (long-term therapy)

- **Blood studies:** CBC, PT if patient is on long-term therapy

- **Chronic poisoning:** rapid, weak pulse; dyspnea; cold, clammy extremities; report immediately to prescriber

Black Box Warning: Hepatotoxicity: occurs with high doses (>4 g/day); dark urine; clay-colored stools; yellowing of skin, sclera; itching; abdominal pain; fever; diarrhea if patient is on long-term therapy; may require liver transplant, those malnourished or using alcohol chronically are at higher chance of hepatotoxicity; consult poison control with suspected acute toxicity, draw 4-hr serum level and administration of acetylcysteine based on the 4-hr level on the Rumack-Matthew nomogram

- **Potentially fatal hypersensitivity, allergic reactions:** rash, urticaria; if these occur, product may have to be discontinued

- **Stevens-Johnson syndrome, toxic epidermal necrolysis may occur when beginning treatment or any other dose**

- **Pregnancy/breastfeeding:** cautious use in pregnancy, breastfeeding (PO), use only if clearly needed (IV)

Evaluate:

- Therapeutic response: absence of pain using pain scoring; absence of fever

Teach patient/family:

Black Box Warning: Hepatotoxicity: not to exceed recommended dosage; the elixir, liquid, suspension come in several concentrations, read label carefully; acute poisoning with liver damage may result; tell parents of children to check products carefully; that acute toxicity includes nausea, vomiting, abdominal pain; prescriber should be notified immediately; that toxicity may occur with other combination products

- Not to use with excessive alcohol, herbals, OTC products without approval of prescriber

- **To recognize signs of chronic overdose:** bleeding, bruising, malaise, fever, sore throat

- That those with diabetes may notice blood glucose monitoring changes
- To notify prescriber of pain or fever lasting more than 3 days
- Not to be used in patients <2 yr unless approved by prescriber
- **Hypersensitivity:** to stop product, call prescriber if rash occurs
- **Pregnancy/breastfeeding:** May be used when breastfeeding, short-term

TREATMENT OF OVERDOSE:

Product level, gastric lavage; administer oral acetylcysteine to prevent hepatic damage (*see acetylcysteine monograph*); monitor for bleeding

acetaZOLAMIDE (Rx)

(a-set-a-zole'a-mide)

Diamox 

Func. class.: Diuretic, carbonic anhydrase inhibitor, antiglaucoma agent, antiepileptic

Chem. class.: Sulfonamide derivative

USES: Open-angle glaucoma, angle-closure glaucoma (preoperatively, if surgery delayed), mixed, tonic-clonic, myoclonic, refractory seizures, epilepsy (petit mal, grand mal, absence), edema in HF, product-induced edema, acute altitude sickness

CONTRAINDICATIONS: Hypersensitivity to sulfonamides, severe renal/hepatic disease, electrolyte imbalances (hyponatremia, hypokalemia), hyperchloremic acidosis, Addison's disease, long-term use for closed-angle glaucoma, adrenocortical insufficiency, metabolic acidosis, acidemia, anuria

DOSAGE AND ROUTES

Angle-closure glaucoma

- **Adult:** PO/IV 250 mg q4hr or 250 mg bid for short-term therapy

Chronic open-angle glaucoma

- **Adult:** PO/IV 250 mg 1-4 times per day or 500 mg EXTENDED RELEASE bid, max 1 g/day

- **Child (unlabeled):** PO 8-30 mg/kg/day in divided doses tid or qid, or 300-900 mg/m²/day, max 1 g/day; IV 5-10 mg q6hr, max 1 g/day

Edema in heart failure, drug-induced edema

- **Adult:** PO/IV 250-375 mg/day
- **Child (unlabeled):** PO/IV 5 mg/kg/day or 150 mg/m² in AM

Adjunct for epilepsy and myoclonic, refractory, generalized tonic-clonic, absence or mixed seizures

- **Adult:** PO/IV 8-30 mg/kg/day in 1-4 divided doses, usual range 375-1000 mg/day; **EXTENDED RELEASE** not recommended with seizures

Altitude sickness

- **Adult:** PO 250 mg twice daily starting the day before ascent and continuing for 2 to 3 days after reaching the target altitude or until descent is initiated

Renal dose

- **Adult:** PO/IV CCr 50-80 mL/min give dose \geq q6hr regular release or IV; CCr 10-50 mL/min give dose q12hr; CCr <10 mL/min, avoid use

acetylcholine ophthalmic

See Appendix B

acetylcysteine (Rx)

(a-se-teel-sis'tay-een)

Acetadote, Mucomyst

Func. class.: Mucolytic; antidote—acetaminophen

Chem. class.: Amino acid L-cysteine

ACTION: Decreases viscosity of secretions by breaking disulfide links of mucoproteins; serves as a substrate in place of glutathione, which is necessary to inactivate toxic metabolites with acetaminophen overdose

USES: Acetaminophen toxicity; bronchitis; cystic fibrosis; COPD; atelectasis

Unlabeled uses: Prevention of contrast medium nephrotoxicity

CONTRAINDICATIONS: Hypersensitivity

Precautions: Pregnancy, breastfeeding, hypothyroidism, Addison's disease, CNS depression, brain tumor, asthma, renal/hepatic disease, COPD, psychosis, alcoholism, seizure disorders, bronchospasms, anaphylactoid reactions, fluid restriction, weight <40 kg, increased intracranial pressure, status asthmaticus

DOSAGE AND ROUTES

Acetaminophen toxicity

• **Adult and child:** **PO** 140 mg/kg, then 70 mg/kg q4hr × 17 doses to total of 1330 mg/kg; **≥41-100 kg IV** loading dose 150 mg/kg over 60 min (dilution 150 mg/kg in 200 mL of D₅W); then 50 mg/kg over 4 hr (dilution 50 mg/kg in 500 mL D₅W); then 100 mg/kg over 16 hr (dilution 100 mg/kg in 1000 D₅W)

• **Adult/child 21-40 kg:** **IV** 150 mg/kg in 100 mL diluent over 1 hr, then 50 mg/kg in 250 mL over 4 hr, then 100 mg/kg in 500 mg over 16 hr

• **Infant/child 5-20 kg:** **IV** 150 mg/kg in 3 mL/kg diluent over 1 hr, then 50 mg/kg in 7 mL/kg diluent over 4 hr, then 100 mg/kg in 14 mL/kg diluent over 16 hr

Mucolytic

• **Adult and child 1-12 yr:** **INSTILL** 1-2 mL (10%-20% solution) q6-8hr prn or 3-5 mL (20% solution) or 6-10 mL (10% sol) tid or qid; **NEBULIZER** (face mask, mouthpiece, tracheostomy) 1-10 mL of a 20% sol, or 2-20 mL of a 10% sol, q2-8hr; **NEBULIZER** (tent, croupette) may require large dose, up to 300 mL/treatment

Tracheostomy care

• **Adult/child:** **INSTILL** 1-2 mL (10%-20% sol) q1-4hr directly into tracheostomy

Diagnostic bronchial lab studies

• **Adult/child:** **NEBULIZER** 2-3 uses of 1-2 mL of 20% sol or 2-4 mL of 10% sol

Prevention of radiocontrast-induced renal reactions (unlabeled)

• **Adult:** **PO** 600 mg bid × 2 days before radiocontrast

Available forms: Oral solution 10%, 20%; inj 20% (200 mg/mL); effervescent tablet for oral solution 500, 2500 mg

Administer:

PO route

• **Antidotal use:** give within 8 hr for best results; dilute 10% or 20% solution to a 5% solution with diet soda, may use water if giving via gastric tube; dilution of 10% solution 1:1, 20% sol 1:3, store open undiluted solution refrigerated ≤96 hr, repeat dose if vomited within 1 hr

PO route (effervescent tablets for oral solution)

• Dissolve in 100 mL water (50 mg/mL) **1-19 kg**; in 150 mL water **20-59 kg**; 300 mg/mL **≥60 kg**

Direct intratracheal instill route

• By syringe: 1-2 mL of 10%-20% solution up to q1hr

• Decreased dose to geriatric patients; metabolism may be slowed

• Only if suction machine is available

• Only after patient clears airway by deep breathing, coughing

• Assistance with inhaled dose: bronchodilator if bronchospasm occurs; mechanical suction if cough insufficient to remove excess bronchial secretions

IV route

• **21-hr regimen:** loading dose: dilute 150 mg/kg in 200 mL D₅W; maintenance dose 1: dilute 50 mg/kg in 500 mL D₅W; maintenance dose 2: dilute 100 mg/kg in 1000 mL D₅W; give loading dose over 15 min; give maintenance dose 1 over 4 hr; give maintenance dose 2 over 16 hr; administer sequentially without time between doses

• Store in refrigerator; use within 96 hr of opening

SIDE EFFECTS

CNS: *Dizziness, drowsiness*, fever, chills

CV: Edema, flushing tachycardia

EENT: *Rhinorrhea*, pharyngitis

GI: *Nausea*, stomatitis, vomiting, anorexia

INTEG: *Urticaria*, rash, clamminess, pruritus

RESP: Bronchospasm, chest tightness, cough, dyspnea

MISC: Anaphylaxis, angioedema, unpleasant odor

PHARMACOKINETICS

IV: Excreted in urine, half-life 5.6 hr (adult), 11 hr (newborn), protein binding 83%, peak up to 60 min (PO), 5-10 min (INH)

Interactions

- Do not use with activated charcoal

NURSING CONSIDERATIONS

Assess:

- **Mucolytic use:** cough—type, frequency, character, including sputum; bronchospasm

- Rate, rhythm of respirations, increased dyspnea; sputum; discontinue if bronchospasm occurs

- VS, cardiac status including checking for dysrhythmias, increased rate, palpitations

- ABGs for increased CO₂ retention in asthma patients

- **Antidotal use:** use within 24 hr of acetaminophen toxicity, give within 10 hr of acetaminophen to minimize hepatotoxicity; monitor LFTs, PT, BUN, creatinine, glucose, electrolytes, acetaminophen levels; inform prescriber if dose is vomited or if vomiting is persistent; 150 mg/kg may be toxic, check acetaminophen level q4hr

- **Hypersensitivity:** anaphylaxis may occur with IV dose; if present, stop infusion, treat, restart; assess for dyspnea, swelling of face, lips, tongue; rash, itching

- Nausea, vomiting, rash; notify prescriber if these occur

- **Pregnancy/breastfeeding:** use only if clearly needed; cautious use in breastfeeding, excretion unknown

Evaluate:

- Therapeutic response: absence of purulent secretions when coughing, clear lung sounds (mucolytic use); absence of hepatic damage with acetaminophen toxicity

Teach patient/family:

- That foul odor and smell may be unpleasant
- To clear airway for inhalation
- To report vomiting because dose may need to be repeated
- **Acetaminophen toxicity:** Explain reason for product, expected result

acclidinium (Rx)

(a'kli-din'ee-um)

Tudorza Pressair, Tudorza Genuair

Func. class.: Anticholinergic, bronchodilator

Chem. class.: Synthetic quaternary ammonium compound

USES: Long-term maintenance treatment of bronchospasm in COPD, emphysema, chronic bronchitis, not indicated for initial treatment of acute episodes

CONTRAINDICATIONS: Hypersensitivity

DOSAGE AND ROUTES

- **Adults, including geriatric patients:** **ORAL INHALATION** 400 mcg (1 actuation) bid; doses should be 12 hr apart

acclidinium/formoterol (Rx)

Duaklir Pressair

Func. class.: Respiratory agent

Chem. class.: Respiratory corticosteroid; long-acting β_2 -agonist; respiratory long-acting muscarinic antagonist

USES: Maintenance treatment of chronic obstructive pulmonary disease (COPD)

CONTRAINDICATIONS: Hypersensitivity

DOSAGE AND ROUTES

• **Adult:** INH 1 inhalation (400 mcg acclidinium and 12 mcg formoterol per actuation) inhaled bid (morning and evening). Max: 1 INH bid

acyclovir (Rx)

(ay-sye'kloe-veer)

Sitavig, Zovirax

Func. class.: Antiviral

Chem. class.: Purine nucleoside analog

Do not confuse:

Zovirax/Zyvox/Valtrex/Zostrix

ACTION: Converted to acyclovir monophosphate by virus-specific thymidine kinase then further converted to acyclovir triphosphate by other cellular enzymes

USES: Mucocutaneous herpes simplex virus, herpes genitalis (HSV-1, HSV-2), varicella infections, herpes zoster, herpes simplex encephalitis

Unlabeled uses: Bell's palsy, prevention of CMV, Epstein-Barr virus, esophagitis, hairy leukoplakia, prevention of herpes labialis, herpes simplex, herpes simplex ocular prophylaxis, keratoconjunctivitis, pharyngitis, pneumonitis, prevention of postherpetic neuralgia, proctitis, stomatitis, tracheobronchitis, varicella prophylaxis

CONTRAINDICATIONS: Hypersensitivity to this product, valACYclovir; milk protein (buccal)

Precautions: Pregnancy, breastfeeding, renal/hepatic/neurologic disease, electrolyte imbalance, dehydration, hypersensitivity to famciclovir, ganciclovir, penciclovir, valGANciclovir, obesity

DOSAGE AND ROUTES

Base dose in obese patients on ideal body weight, not actual body weight

Herpes simplex (recurrent)

• **Adult:** PO 400 mg 3×/day for 5 days or 200 mg 5×/day × 5 days

• **Adult and child >12 yr:** IV INFUSION 5 mg/kg over 1 hr q8hr × 7 days

• **Infant >3 mo/child <12 yr:** IV INFUSION 10 mg/kg q8hr × 7 days; if HIV infected, 5-10 mg/kg q8hr (moderate to severe)

• **Neonate:** IV INFUSION 10 mg/kg q8hr × 10 days, may use higher dose

Genital herpes, initial episodes

• **Adult:** PO 400 mg tid or 200 mg 5×/day × 7-10 days, may extend treatment if healing is not complete after 10 days; TOP × 5 days; IV 5 mg/kg q8hr or 750 mg/m²/day divided q8hr × 5-7 days

Genital herpes, episodic treatment

• **Adult:** PO 400 mg tid or 800 mg bid × 5 days or 800 mg tid × 2 days; initiate within 1 day of lesion onset

Genital herpes, suppression therapy

• **Adult:** PO 400 mg bid for up to 12 mo or 200 mg 3-5 times daily for up to 12 mo

Genital herpes, initial limited, mucocutaneous HSV in immunocompromised patients, non-life-threatening

• **Adult/child ≥12 yr:** TOP cover lesions q3hr 6×/day

Herpes simplex encephalitis

• **Adult:** IV 10 mg/kg over 1 hr q8hr × 10 days

• **Child 3 mo-12 yr:** IV 10-15 mg/kg q8hr × 4-21 days

• **Child birth-3 mo:** IV 20 mg/kg q8hr × 21 days

• **Neonates/premature infants:** IV 10 mg/kg q12hr × 14-21 days

Herpes labialis, recurrent

• **Adult/child ≥12 yr:** TOP apply cream 5×/day for 4 days; start as soon as symptoms appear

Herpes labialis, recurrent in immunocompetent patients

• **Adult:** Buccal 50 mg as a single dose in upper gum region within 1 hr after prodromal symptoms and before cold sore formation

Herpes zoster (immunocompetent)

• **Adult:** PO 800 mg q4hr 5×/day while awake × 7-10 days; IV 10 mg/kg q8hr × 7 days

Herpes zoster (shingles) immunocompromised patients

- **Adult/adolescent:** PO 800 mg q4hr 5×/day for 7-10 days; IV 10-15 mg/kg q8hr × 10-14 days
- **Infant/child <12 yr:** IV 10 mg/kg/dose q8hr × 7-10 days

Herpes zoster (shingles) immunocompetent

- **Adult:** PO 800 mg q4hr 5×/day × 7-10 days; start within 48-72 hr of rash onset

Varicella (chickenpox)

- **Adult/child ≥2 yr:** PO 10 mg/kg/dose (max 800 mg) 4×/day × 5 days

Mucosal/cutaneous herpes simplex infections in immunosuppressed patients

- **Adult and child >12 yr:** IV 5 mg/kg q8hr × 7 days
- **Infant >3 mo/child <12:** IV 10 mg/kg q8hr × 7 days

Renal dose

- **Adult and child:** PO/IV CCr >50 mL/min 100% dose q8hr, CCr 25-50 mL/min 100% dose q12hr, CCr 10-25 mL/min 100% dose q24hr, CCr 0-10 mL/min 50% dose q24hr

Recurrent ocular herpes, prevention (unlabeled)

- **Adult/child ≥12 yr:** PO 600-800 mg every day × 8-12 mo

CMV prophylaxis (unlabeled)

- **Adult:** IV 500 mg/m² q8hr

Herpes simplex in pneumonitis/ esophagitis/tracheobronchitis/ proctitis/stomatitis/pharyngitis (unlabeled)

- **Adult and adolescent:** IV 5-10 mg/kg q8hr × 2-7 days or PO 200 mg q4hr 5×/day × 7-10 days or 400 mg 3-5×/day × ≥10 days
- **Child 6 mo-12 yr:** IV 1000 mg/day in 3-5 divided doses × 7-14 days

Herpes simplex prophylaxis for chronic suppression therapy (unlabeled)

- **Adult and adolescent:** PO 400 mg bid up to 12 mo

Available forms: Capsules 200 mg; tablets 400, 800 mg; powder for injection 500, 1000 mg; solution for injection 50 mg/mL; oral suspension 200 mg/5 mL; ointment/cream 5%; buccal tablet 50 mg

Administer:

PO route

- Do not break, crush, or chew capsules
- May give without regard to meals, with 8 oz of water
- Shake suspension before use

Buccal

- Use on the same side as the herpes labialis lesion; after removing tablet from blister, place rounded side of tablet to the upper gum above incisor tooth; hold in place for 30 sec; once adhered, the tablet will dissolve; if tablet falls off within 6 hr, reposition the same tablet

Topical route

- Use finger cot or glove to cover all lesions completely; do not get in eye; wash hands after use

Intermittent IV INFUSION route

- Increase fluids to 3 L/day to decrease crystalluria; most critical during first 2 hr after IV
- Reconstitute 10 mL compatible solution/500 mg or 20 mL/1 g of product, 50 mg/mL, shake, further dilute in 50-125 mL compatible solution; use within 12 hr; give over at least 1 hr by infusion pump to prevent nephrotoxicity; do not reconstitute with solution containing benzyl alcohol in neonates
- Store at room temperature for up to 12 hr after reconstitution; if refrigerated, solution may show a precipitate that clears at room temperature; yellow discoloration does not affect potency

Y-site compatibilities: Alectuzumab, alfentanil, allopurinol, amikacin, aminophylline, amphotericin B cholesteryl, amphotericin B liposome, ampicillin, anidulafungin, argatroban, atracurium, bivalirudin, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, CARBOplatin, cefazolin, cefonicid, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, ceftRIAXone, cefuroxime, chloramphenicol, cholesteryl sulfate complex, cimetidine, clindamycin, dexamethasone sodium phosphate, dimenhydrinate, DOXOrubicin, doxycycline, erythromycin, famotidine, filgrastim, fluconazole, gallium, gentamicin, granisetron, heparin, hydrocortisone sodium succinate, HYDRomorphine,

imipenem/cilastatin, LORazepam, magnesium sulfate, melphalan, methylPREDNISolone sodium succinate, metoclopramide, metroNIDAZOLE, multivitamin, nafcillin, oxacillin, PACLitaxel, penicillin G potassium, PENTobarbital, perphenazine, piperacillin, potassium chloride, propofol, raNTIDine, remifentanyl, sodium bicarbonate, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin, tobramycin, trimethoprim-sulfamethoxazole, vancomycin, vasopressin, voriconazole, zidovudine

SIDE EFFECTS

CNS: Tremors, confusion, lethargy, hallucinations, **seizures**, dizziness, headache, encephalopathic changes

EENT: Gingival hyperplasia

GI: Nausea, vomiting, diarrhea, increased ALT/AST, abdominal pain, colitis

GU: **Hematuria, acute renal failure**, changes in menses

HEMA: **Thrombotic thrombocytopenia purpura, hemolytic uremic syndrome**, leukopenia (immunocompromised patients)

INTEG: Rash, urticaria, pruritus, pain or phlebitis at IV site, unusual sweating, alopecia, **Stevens-Johnson syndrome**

MS: Joint pain

SYST: **Angioedema, anaphylaxis**

PHARMACOKINETICS

Distributed widely; crosses placenta; CSF concentrations are 50% of plasma; protein binding 9%-33%

PO: Absorbed minimally, onset unknown, peak 1.5-2 hr, half-life 2.5-3.3 hr (adult); 2-3 hr (child); up to 4 hr (neonates)

Buccal: Peak 8 hr

IV: Onset immediate, peak immediate, duration unknown, half-life 20 min-3 hr (terminal); metabolized by liver, excreted by kidneys as unchanged product (95%)

INTERACTIONS

Increase: CNS side effects—zidovudine

Increase: levels, toxicity—probenecid, monitor for toxicity

Increase: nephrotoxicity—aminoglycosides

Increase: concentrations of—entecavir, PEMEtrexed, tenofovir, theophylline

Decrease: action of hydantoin, valproic acid, monitor drug levels

Drug/Lab Test

Increase: BUN, creatinine

Decrease: WBC

NURSING CONSIDERATIONS

Assess:

- **Infection:** type of lesions, area of body covered, purulent drainage, frequency of lesions

- **Hepatic, renal studies:** AST, ALT; urinalysis, protein, BUN, creatinine, CCR, watch for increasing BUN and serum creatinine or decreased CCR; I&O ratio; report hematuria, oliguria, fatigue, weakness; may indicate nephrotoxicity; check for protein in urine during treatment

- Skin eruptions: rash, urticaria, itching
- Allergies before treatment, reaction to each medication; place allergies on chart in bright red letters

- Neurologic status with herpes encephalitis

- Provide adequate intake of fluids (2 L) to prevent deposits in kidneys, more likely to occur with rapid administration or in dehydration

Evaluate:

- Therapeutic response: absence of itching, painful lesions; crusting and healed lesions; decreased symptoms of chickenpox; healing, decreased pain with herpes zoster

Teach patient/family:

- To take as prescribed; if dose is missed, take as soon as remembered up to 1 hr before next dose; do not double dose

- That product may be taken orally before infection occurs; product should be taken when itching or pain occurs, usually before eruptions

- That sexual partners need to be told that patient has herpes because they can become infected; condoms must be worn to prevent reinfections

- Not to touch lesions to avoid spreading infection to new sites, not to use topical products on lesions, spreading may occur

- That product does not cure infection, just controls symptoms and does not prevent infecting others

- That product must be taken in equal intervals around the clock to maintain blood levels for duration of therapy